Thermo Fisher Scientific Inc. has announced an agreement to acquire Olink Holding AB, a proteomics company based in Sweden. The deal is valued at approximately $3.1 billion, with $143 million being paid in cash.
Olink’s stock was halted until 8:50 a.m. Eastern as the news broke. Thermo Fisher's shares experienced a 1.5% drop in premarket trading.
Under the terms of the deal, Thermo Fisher will pay $26 in cash for each outstanding common share of Olink. This represents a significant 73.6% premium to Olink's closing price of $14.98 on Monday. The transaction is expected to be completed by mid-2024.
Synergies and Benefits
Thermo Fisher anticipates generating approximately $125 million in adjusted income from revenue and cost synergies within five years after the deal's completion.
Thermo Fisher's CEO, Marc Caspe, highlighted the importance of the acquisition, stating, "The acquisition of Olink underscores the profound impact that proteomics is having as our customers continue to advance life science research and precision medicine." He further added, "Olink’s proven and transformative innovation is highly complementary to our leading mass spectrometry and life sciences platforms."
This acquisition reinforces Thermo Fisher Scientific's commitment to advancing scientific research and improving precision medicine through cutting-edge technological developments.